Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

6,222JPY
24 Nov 2017
Change (% chg)

¥-73 (-1.16%)
Prev Close
¥6,295
Open
¥6,222
Day's High
¥6,237
Day's Low
¥6,165
Volume
984,900
Avg. Vol
790,925
52-wk High
¥6,997
52-wk Low
¥5,496

Chart for

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's businesses include pharmaceutical business and other business. The Company's segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥1,845,240.00
Shares Outstanding(Mil.): 296.57
Dividend: 80.00
Yield (%): 2.41

Financials

  Industry Sector
P/E (TTM): -- 31.51 15.54
EPS (TTM): -- -- --
ROI: -- 15.16 11.80
ROE: -- 16.57 15.75

BRIEF-Eisai Co to invest about $8.8 mln at Vizag plant in India - Nikkei‍​

* Eisai co to invest about $8.8 million to install manufacturing equipment at Vizag plant in India - Nikkei‍​ Source text for Eikon: Further company coverage:

Oct 31 2017

BRIEF-Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab

* Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab

Oct 23 2017

BRIEF-Eisai Co signs agreement with Grupo Biotoscana granting GBT exclusive licensing rights

* Eisai Co - signed agreement with Grupo Biotoscana granting GBT exclusive licensing rights

Oct 03 2017

BRIEF-FDA approves Eisai's Fycompa for use as monotherapy for the treatment of partial-onset seizures

* FDA approves Eisai's Fycompa® (perampanel) for use as monotherapy for the treatment of partial-onset seizures

Jul 26 2017

BRIEF-Eisai submits supplemental new drug application to FDA for lenvatinib in first-line hepatocellular carcinoma

* Eisai submits supplemental new drug application to FDA for lenvatinib in first-line hepatocellular carcinoma

Jul 25 2017

BRIEF-Oncology Venture and Eisai forge exclusive global license agreement for clinical stage oncology drug PARP inhibitor E7449 / 2X-121

* ‍Oncology Venture - Co entered into exclusive global license agreement with Eisai Inc. for Eisai's phase 2 parp inhibitor E7449 - now called 2X-121​

Jul 07 2017

BRIEF-Oncology Venture Sweden and Eisai sign exclusive global license agreement

* ONCOLOGY VENTURE AND EISAI FORGE EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR CLINICAL STAGE ONCOLOGY DRUG PARP INHIBITOR E7449 / 2X-121 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 07 2017

BRIEF- R&I affirms Eisai's rating at "A+" and announces stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

Jun 30 2017

BRIEF-Ewopharma announces commercial partnership with Eisai

* Ewopharma says it will commercialise Halaven (eribulin mesylate) in nine countries within European Union and in two countries outside of EU

Jun 22 2017

Earnings vs. Estimates